Inogen (INGN) Q3 2026 earnings review
Inogen sells its rental unit, but international sales drop
Inogen, a maker of home oxygen machines, overhauled its leadership and business model as overseas sales stalled. Continuing revenue fell 2% after international sales dropped 9%, wiping out a 4% rebound in domestic equipment sales and turning last year's profit excluding one-offs into a loss. The board replaced chief executive Kevin Smith with operating chief Andy Reding, closed the sale of the shrinking U.S. rental unit, and started a $20 million cost-cutting plan.
| Continuing revenue | $77.2M -2.4% from a year ago |
|---|---|
| International sales | $34.9M -9.0% from a year ago |
| Loss excluding one-offs | -$0.4M +$1.2M profit a year ago |
| Full-year revenue outlook | Cut $298–301M continuing sales (+1% at middle) |
⚖️ Verdict: 🔴 Bearish
The story got worse because the international division broke its ten-quarter streak of double-digit growth and pulled the fourth-quarter outlook down with it. By our math, the new full-year plan cuts implied equipment sales by about $12 million and points to a $5 million loss excluding one-offs in the fourth quarter, alongside a complete write-off of goodwill. On the other hand, selling the rental business for up to $25 million removes a cash drain and settles a major structural worry.
The question now is whether Reding's $20 million cost plan and the rental exit can stop the cash burn while distributor demand recovers. Either overseas orders rebound after a temporary inventory pause and cost cuts restore profits, or lower distributor prices and international budget limits keep the business in the red. Fourth-quarter international sales and cash balances will show which path holds.
🐂 Bull Case
Rental Divestiture Removes a Shrinking Channel
Inogen makes portable oxygen concentrators for patients with chronic lung disease. For years, its U.S. oxygen rental division shrank as patient counts fell and shipping costs per patient rose. On November 2, the medical device maker sold the rental business to Rotech for up to $24.8 million in cash and moved past results into discontinued operations.
The sale removes a division that lost $2.9 million after tax over the first nine months of 2026 and consumed $2.5 million in equipment spending. It also creates a long-term supply deal that lets Inogen sell oxygen machines through Rotech's national network rather than billing insurance for individual rentals itself.
What to watch: final cash proceeds from the sale and fourth-quarter orders under the Rotech supply agreement. Those numbers will show how much cash the deal adds and whether Rotech buys enough machines to replace the lost rental stream.
U.S. Equipment Sales Returned to Growth
After shrinking for several quarters, domestic equipment sales grew 3.8% from a year ago to $42.2 million. The respiratory device company credited "demand for our portable oxygen concentrators, or POCs, and new products" as home medical equipment providers prescribed portable units to more patients.
- U.S. sales: $42.2 million, up 3.8% from a year ago after falling 2.3% in the second quarter
- Total portable units sold: 51,900 across all regions, up 5.9% from 49,000 a year ago
- Revenue per portable unit sold: $1,487 across the company, down 7.9% from a year ago by our math
Unit volume grew faster than dollar sales because home medical equipment distributors buy in bulk at lower prices than individual consumers pay. That shift toward distributors lifts factory volume but lowers the average price Inogen collects on each machine.
What to watch: whether U.S. sales stay positive in the fourth quarter when total company revenue is planned to fall. Another domestic gain would show that distributor demand can outrun the shrinking direct-to-consumer channel.
Board Drops Takeover Defenses and Adds Buybacks
Inogen spent $1.0 million over the first nine months of 2026 on shareholder engagement and proxy defense fees, including $223,000 in the third quarter. Even though 99% of votes cast at the June annual meeting favored electing directors every year, the measure failed to reach the required two-thirds of all existing shares.
The board now plans to ask shareholders at the 2027 annual meeting to elect all directors annually and remove supermajority voting rules from its charter. Directors also added $15 million to the share buyback plan, bringing the total authorization to $45 million after spending $11.2 million over the first nine months.
What to watch: proxy defense expenses in the fourth quarter and share repurchases after the rental sale closes. Ending the governance dispute should eliminate those legal and advisory bills.
🐻 Bear Case
International Sales Shrank After Ten Strong Quarters
Foreign sales were Inogen's main growth engine for more than two years, posting double-digit gains for ten straight quarters while the U.S. business shrank. Supporters viewed launches in Brazil and Canada as proof of lasting demand, while skeptics warned that overseas distributors had over-ordered in the first half of the year.
That engine reversed in the third quarter as international revenue dropped 9.0% from a year ago to $34.9 million, or 10.4% in constant currency. The company blamed "capital softness in international markets", which pulled total continuing revenue down 2.4% and missed its prior plan for flat sales.
Because overseas orders carry higher margins, the drop also hurt profitability. Gross margin excluding one-offs fell 1.7 percentage points to 44.2% as cost of revenue rose 1.7 points of sales, which "more than offset continued cost of revenue improvements", the company said.
What to watch: fourth-quarter international revenue and gross margin excluding one-offs. A second straight decline overseas would confirm that foreign demand faces deeper budget limits rather than a one-quarter inventory pause.
New Outlook Cuts Implied Fourth-Quarter Sales
Inogen missed its second-half revenue targets two years in a row and already lowered its full-year plan once in the second quarter. With the rental sale complete, the oxygen device maker restated its 2026 revenue outlook on a continuing-operations basis to $298 million to $301 million, with fourth-quarter sales at $65 million to $68 million.
Even after stripping out rentals, the new numbers represent another cut. Three months ago, the full-year plan of $355 million to $361 million included roughly $47 million of estimated annual rental revenue, leaving about $311 million for the continuing equipment business by our math. The new midpoint of $299.5 million is roughly $12 million lower.
At the middle of the fourth-quarter range, continuing revenue will fall 3.0% from last year's $68.6 million in equipment sales and drop 13.9% from the third quarter, by our math. That fourth-quarter drop arrives even though last year's fourth quarter was already depressed by delayed orders.
What to watch: fourth-quarter revenue against the $65 million to $68 million range. Finishing near or below the bottom would mark a third straight year of fourth-quarter shortfalls.
Goodwill Wipeout and Deeper Fourth-Quarter Losses
Inogen previously pointed to tighter cost discipline and raised its full-year profit target before depreciation and one-offs in the second quarter. In the third quarter, however, it recorded a $10.6 million impairment charge that wrote off all the goodwill on its balance sheet from past acquisitions.
- Reported loss from continuing operations: $14.8 million, compared with $3.6 million a year ago
- Loss from continuing operations excluding one-offs: $0.4 million, down from $1.2 million of profit a year ago
- Research and development: rose 0.9 percentage points of sales to 7.0%, while sales and marketing fell 1.6 points to 24.5%
The company also replaced its full-year profit metric with a new forecast for an annual loss from continuing operations, excluding one-offs, of $7 million to $8 million. Because that loss was $2.9 million over the first nine months, the plan leaves a $4.6 million loss for the fourth quarter by our math.
What to watch: fourth-quarter operating expenses and whether the goodwill write-off stems from the Physio-Assist airway clearance acquisition. The quarterly filing will name the impaired asset.
Risks this quarter didn't answer
Three standing concerns received no numbers or milestone updates in the third-quarter earnings release.
- U.S. direct-to-consumer vs distributor sales: Inogen again combined both domestic channels into a single U.S. sales line, hiding how fast direct consumer sales are shrinking.
- New product revenue: the release gave no dollar figures for the Voxi stationary oxygen machine or Aurora sleep apnea masks.
- Simeox clinical and regulatory milestones: the release provided no update on the China study results or China regulatory clearance that were due before year-end 2026.
👓 Other Themes
New Chief Executive Launches $20 Million Cost Plan
The board appointed operating chief Andy Reding to replace Kevin Smith as chief executive, as board chair Elizabeth Mora said "we must do more to improve performance to capture the opportunity in front of us, and the Board has determined that now is the right time to make this transition". Reding said he wants to "sharpen our focus, strengthen execution, and improve commercial and operational performance" and started a fourth-quarter program to cut $20 million in yearly costs by late 2027.
International Currency Tailwind Eased
Inogen bills most of its overseas distributors in euros, so a stronger euro lifts reported dollar revenue. In the third quarter, currency exchange rates helped total continuing revenue by 0.8 percentage points and international sales by 1.4 points, down from a 2.4-point total company tailwind in the second quarter.
💲 Other KPIs
Money owed by customers for shipped products rose 42.4% from $34.1 million at the end of 2025, even though quarterly revenue shrank. Uncollected bills have climbed every quarter this year — from $34.1 million to $41.9 million, $46.2 million, and now $48.6 million — tying up cash while overseas distributors slow their purchases.
Total cash and marketable securities fell by $9.1 million during the third quarter and are down 19.2% from $120.9 million at the end of 2025. Continuing operations burned $13.6 million in operating cash and $1.2 million in equipment spending over the first nine months, while share buybacks used another $11.2 million.
The average number of diluted shares fell 2.3% from 27.1 million a year ago and 2.2% from 27.0 million in the second quarter. The medical technology group bought back 1.79 million shares for $11.2 million over the first nine months of 2026, including about $3.8 million spent in the third quarter by our math.
🔮 Guidance
New. The plan for continuing operations points to $66.5 million at the middle of the range. By our math, that means fourth-quarter equipment sales will drop 3.0% from last year's $68.6 million in continuing sales and fall 13.9% from the third quarter, despite comparing against a fourth quarter hurt by delayed shipments.
Cut. After removing the sold rental unit, the new plan calls for 1.4% annual equipment sales growth at the middle of the range, by our math. That $299.5 million midpoint sits roughly $12 million below the ~$311 million implied for equipment sales under last quarter's total company forecast.
New. Inogen introduced a full-year net loss target for continuing operations, excluding one-offs, and gave no updated figure for full-year profit before depreciation and one-offs. Because the continuing net loss excluding one-offs was $2.9 million over the first nine months, the outlook leaves a $4.6 million loss for the fourth quarter by our math, or -6.9% of sales.
❓ Key Questions
Where will the $20 million in cost cuts fall?
Inogen plans to save $20 million a year by the end of 2027, starting in the fourth quarter. Investors need to know how much comes from sales and marketing versus research or overhead, and what upfront severance charges the cuts require.
Which acquisition triggered the $10.6 million goodwill write-off?
The third-quarter impairment wiped out all goodwill on the balance sheet. Writing off goodwill tied to the 2023 Physio-Assist purchase would signal slower commercial expectations for the Simeox airway clearance device ahead of its U.S. reimbursement trials.
Why did accounts receivable climb 42% while sales fell?
Uncollected customer bills reached $48.6 million, up $14.5 million since December while continuing revenue shrank. Management did not explain whether overseas distributors are taking longer to pay as their own equipment sales slow.
Is Simeox still on track for China clearance this year?
Former chief executive Kevin Smith previously expected statistical results from the China clinical study and Chinese regulatory clearance for Simeox before the end of 2026. The third-quarter release did not mention either milestone.